Understanding how Aurora Kinase A affects Myc protein stability in cancer
Official title: Defining Mechanisms Governing Myc Stability and its Modulation by Aurora Kinase A
Funded at University of Minnesota · NIH-11033740 · Data updated 2026-11-12
This study is looking at how a protein called Aurora Kinase A helps keep another protein, Myc, stable, which is important because Myc is involved in many cancers; the goal is to find new ways to treat these cancers that could help patients like you.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | September 9, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $125,000 |
| NIH project number | 1K99GM157491-01 |
| Project ID | NIH-11033740 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with cancers associated with Myc dysregulation, such as neuroblastoma or small cell lung carcinoma.
✕Less likely to help
Patients with cancers not related to Myc dysregulation may not receive any benefit from this research.
What this research studies
This research investigates the role of Aurora Kinase A in stabilizing Myc proteins, which are known to drive many cancers. By examining how these proteins interact and the effects of their phosphorylation states, the study aims to uncover potential therapeutic targets for cancer treatment. Patients may benefit from insights that could lead to new strategies for targeting Myc-related cancers. The research employs advanced techniques like fluorescence anisotropy and X-ray crystallography to analyze these interactions.
Why it matters
Potential benefit: If successful, this research could lead to new cancer treatments that specifically target Myc proteins, improving outcomes for patients with Myc-driven cancers.
How similar studies have gone: Other research has shown promise in targeting protein interactions in cancer, suggesting that this approach could yield significant insights.
Where this research is happening
-
University of Minnesota
Minneapolis, United States Active
Researchers
- Principal investigator: Dunleavy, Katie M. — University of Minnesota
- Study coordinator: Dunleavy, Katie M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.